Business Insider

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation

EL-22, a first-in-class myostatin asset, is being developed as a potential combination therapy with GLP-1 receptor agonists for obesity. It aims to address muscle loss, a common side effect of rapid ...
Business Insider

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the ...

EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food ...
Hartford Courant

UConn gene discovery moves closer to treating neuromuscular disease, holds promise for weight loss

A UConn professor and researcher who 28 years ago discovered a gene for a protein that limits human muscle growth is closer than ever to having that work play a significant role in treating those with ...
Nasdaq

Elevai Biosciences engages KCRN Research to support IND efforts for EL-22

Elevai Biosciences has engaged KCRN Research to support the Company’s initial efforts to prepare for an Investigational New Drug application to the FDA for EL-22 in the treatment of obesity and muscle ...
SpaceNews

“Mighty Mice” in Space Could Lead to New Therapies for Muscle and Bone Loss on Earth

Findings from the “Mighty Mice” investigation on the International Space Station (ISS) may help “save the day” both for earthbound patients with muscle and bone loss as well as astronauts on prolonged ...
Nature

Muscle Growth and Differentiation Factors

The intricate regulation of skeletal muscle mass and regeneration involves a network of growth and differentiation factors that orchestrate cellular proliferation, differentiation and repair. Central ...